Glenmark Pharmaceuticals Ltd., commonly referred to as Glenmark, is a prominent global player in the pharmaceutical industry, headquartered in India. Founded in 1977, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets. Glenmark focuses on the development and manufacturing of innovative generics, specialty pharmaceuticals, and over-the-counter products. With a diverse portfolio that includes formulations in therapeutic areas such as dermatology, oncology, and respiratory, Glenmark is recognised for its commitment to research and development. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of new therapies. Glenmark's dedication to quality and innovation has positioned it as a trusted name in the pharmaceutical sector, making notable strides in both domestic and international markets.
How does Glenmark Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Glenmark Pharmaceuticals's score of 61 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Glenmark Pharmaceuticals reported total greenhouse gas emissions of approximately 175,069,000 kg CO2e across all scopes. This includes about 12,703,000 kg CO2e from Scope 1, which encompasses direct emissions from owned or controlled sources, and approximately 64,812,000 kg CO2e from Scope 2, related to indirect emissions from the generation of purchased electricity. The company also reported significant Scope 3 emissions, totalling around 175,069,000 kg CO2e, which includes emissions from the supply chain and product use. Glenmark has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 35% by FY2035, using FY2021 as the baseline year. Additionally, the company targets a 28% reduction in Scope 3 emissions per ton of pharmaceutical products over the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit temperature rise to well below 2°C. The company has demonstrated a commitment to sustainability through these initiatives, reflecting its responsibility towards reducing its carbon footprint and addressing climate change challenges in the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Scope 1 | 11,713,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 74,231,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 3,277,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glenmark Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.